Cargando…

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery

AIMS: The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration. PATIENTS & METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goio, Elisabetta, Ielasi, Luca, Benevento, Francesca, Renzulli, Matteo, Tovoli, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399611/ https://www.ncbi.nlm.nih.gov/pubmed/32774834 http://dx.doi.org/10.2217/hep-2020-0014

Ejemplares similares

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Hot topics in hepatocellular carcinoma
por: Ielasi, Luca, et al.
Publicado: (2019)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
por: Tovoli, Francesco, et al.
Publicado: (2018)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Hepatocellular adenoma: An unsolved diagnostic enigma
por: Renzulli, Matteo, et al.
Publicado: (2019)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
por: Sastre, J., et al.
Publicado: (2014)

Asthma remission: what is it and how can it be achieved?
por: Thomas, Dennis, et al.
Publicado: (2022)

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Magnetic resonance imaging of pure ovarian dysgerminoma: a series of eight cases
por: Cacioppa, Laura Maria, et al.
Publicado: (2021)

Complete remission in metastatic hepatocellular carcinoma
por: Ben Kridis, Wala, et al.
Publicado: (2023)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers
por: Renzulli, Matteo, et al.
Publicado: (2022)

The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool?
por: Renzulli, Matteo, et al.
Publicado: (2022)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
por: Han, Yue, et al.
Publicado: (2021)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

Two cases of lymphangitic carcinomatosis as the primary symptom of colorectal carcinoma that achieved complete remission using combination anti-EGFR antibody therapy
por: Toshima, Hirokazu, et al.
Publicado: (2019)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
por: Lin, Chun-Yu, et al.
Publicado: (2018)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients
por: Benevento, Francesca, et al.
Publicado: (2023)

Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
por: Rizell, Magnus, et al.
Publicado: (2020)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
por: Brummer, Grace C., et al.
Publicado: (2017)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib
por: Zhuo, Jianyong, et al.
Publicado: (2021)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d5a1g8huoaf14c5b3uapejd5g7